Real-world Analysis of Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable Non-small Cell Lung Cancer
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 110
- 试验地点
- 1
- 主要终点
- Event-free survival
研究概览
简要总结
This is a real-world study with the largest sample size investigating the pathological tumor and lymph node responses to neoadjuvant immunochemotherapy in non-small cell lung cancer to date. Patients with initially unresectable NSCLC underwent immunochemotherapy and response to treatment was assessed after every two treatment cycles. Clinicopathologic features of patients including epidemiological data, clinical manifestations, operation strategies, pathological findings, and prognostic information were recorded and evaluated.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with stage III NSCLC who received neoadjuvant immunochemotherapy.
- •early-stage NSCLC patients who were initially unresectable.
- •18 years of age or older.
- •Karnofsky performance status (KPS) score of 100 or 90.
排除标准
- •Patients with stage IV NSCLC
- •Patients with known ALK translocations or EGFR mutations.
- •Karnofsky performance status (KPS) score <90.
研究组 & 干预措施
combined well responder
Both primary tumor and nodal response achieve major pathological response (MPR).
干预措施: Timing of drug administration (Drug)
poor responder
Primary tumor or/and nodal response can not achieve MPR.
干预措施: Timing of drug administration (Drug)
结局指标
主要结局
Event-free survival
时间窗: At least one year
the time from diagnosis to any progression of disease precluding surgery, progression or recurrence of disease after surgery or death from any cause.
次要结局
未报告次要终点